YHD 001

Drug Profile

YHD 001

Alternative Names: YHD001

Latest Information Update: 08 Sep 2015

Price : $50

At a glance

  • Originator Yuhan
  • Class Antibronchitics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Bronchitis

Most Recent Events

  • 08 Sep 2015 Discontinued - Phase-II for Asthma and Bronchitis in South Korea (PO)
  • 01 Jan 2014 Yuhan Corporation completes a phase II trial in Asthma in South Korea (NCT01424124)
  • 23 Feb 2012 Yuhan Corporation completes enrolment in its phase II trial for Bronchitis in South Korea (NCT01420445)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top